|

Zanubrutinib Clinical Trials

39 actively recruiting trials across 19 locations

Also known as: BDB-3111, BGB 3111, BGB-3111, BGB3111, BRUKINSA®, BTK-InhB, Brukinsa, Brukinsa®, C27H29N5O3, Maintenance therapy with Zanubrutinib, Zanubrutinib pills

Other15 trials

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
Phase 2
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Phase 1/2
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Phase 4
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Phase 2
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
Phase 4
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Phase 2
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Phase 2
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Boston, Massachusetts3 trials

Epco, Zanu, Ritux for R/R FL or MZL

Dana-Farber Cancer Institute

Phase 2
Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital

Phase 1/2
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

Massachusetts General Hospital

Phase 2

Phoenix, Arizona2 trials

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Mayo Clinic Phoenix

Phase 1/2
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

Mayo Clinic Arizona

Phase 2

Tucson, Arizona2 trials

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Banner University Medical Center - Tucson

Phase 2

Miami, Florida2 trials

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Miami Cancer Institute at Baptist Health, Inc.

Phase 2
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

University of Miami

Phase 1/2

Birmingham, Alabama1 trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

University of Alabama At Birmingham Hospital

Phase 3

Huntsville, Alabama1 trial

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Clearview Cancer Institute

Little Rock, Arkansas1 trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

University of Arkansas for Medical Sciences

Phase 3

Duarte, California1 trial

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1

Fresno, California1 trial

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Ucsf Fresno University of California San Francisco Fresno

Phase 3

Denver, Colorado1 trial

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Colorado Blood Cancer Institute (CBCI)

Phase 2

Washington D.C., District of Columbia1 trial

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Georgetown University (Data Collection Only)

Phase 2

Miami Beach, Florida1 trial

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Mt Sinai Comprehensive Cancer Center

Phase 2

Tampa, Florida1 trial

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Moffitt Cancer Center

Phase 2

Evanston, Illinois1 trial

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Northwestern University

Phase 2

Scarborough, Maine1 trial

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

New England Cancer Specialists

Phase 2

Houston, Texas1 trial

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

MD Anderson Cancer Center

Phase 2

Salt Lake City, Utah1 trial

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Huntsman Cancer Institute at University of Uta

Phase 1

Richmond, Virginia1 trial

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Virginia Commonwealth University

Phase 2

Seattle, Washington1 trial

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.